Chengdu Olymvax Biopharmaceuticals Inc. Stock: price and insider trades · China
欧林生物
No insider purchase over the last 90 days. The latest, by 陈克平, was filed 27 Jul 2026.
Chengdu Olymvax Biopharmaceuticals Inc.: what insiders have been doing
Chengdu Olymvax Biopharmaceuticals Inc. belongs to the Health Care sector. Filings by its managers are published through SSE / SZSE (CSRC). In the past year (4 November 2025 to 4 November 2026), 5 filings came from 2 insiders.
The record shows 2 purchases on the open market worth €50k, made by 1 insider, against 3 sales worth €135k by 2 insiders. On balance, insiders were net sellers of €85k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. One trade stands out by size: a sale of €88k from 陈克平, disclosed on 6 May 2026.
With 5 filings in twelve months, the company is more active than the median of 2 filings across the 516 companies we follow on the same exchange. The full history, which starts in 2023, counts 2 purchases against 9 sales.
The most recent open-market purchase was published on 27 July 2026, 104 days ago. The median gap between trade and publication is zero days: most filings appear on the same day. Until a filing is published, the market cannot know about the trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and UCB. These figures are compiled from regulatory filings published by SSE / SZSE (CSRC). They describe what insiders did and are not a recommendation.
Who traded when
BuySaleSince the insiders bought
- +16.1%Entry CN¥23.25 · Close 02 Nov 2026 CN¥27.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 5,000 shares@ CN¥184.89697.7% of flowA股XSHGSSE:273000000894431520Canonical exit: 25 Oct 2026 (T+90)
- 2,000 shares61.6% of flowA股XSHGSSE:273000000606044160
- 20,000 shares43.5% of flowA股XSHGSSE:273000000582980600
- 12,000 shares17.2% of flowA股XSHGSSE:273000000166046880Canonical exit: 30 Apr 2026 (T+90)
- 10,000 shares18.9% of flowA股XSHGSSE:273000000105369800
- 49,300 shares100.0% of flowA股XSHGSSE:173000009638679550
- 10,000 shares100.0% of flowA股XSHGSSE:173000009272404860
- 2,000 shares38.4% of flowA股XSHGSSE:173000009263032540
- 60,000 shares100.0% of flowA股XSHGSSE:173000008830319650
- 2,000 shares100.0% of flowA股XSHGSSE:173000007572414880
- 9,934 shares12.7% of flowA股XSHGSSE:173000007054153280
11 of 11 declarations
About Chengdu Olymvax Biopharmaceuticals Inc.
欧林生物 is a company specializing in the healthcare and pharmaceutical sector. It is listed on the XSHG market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
